This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
It aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services enabling quick & on-demand deployment
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Domestic market and developing countries will need doses of Indian vaccines
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Subscribe To Our Newsletter & Stay Updated
